Skip to content
Review

Current perspectives on the pharmacotherapeutic management of insomnia in Veterans.

Oct 2026 · Expert Opinion on Pharmacotherapy · pp. 1-13 · 0 citations · 55 references
Medicine

TL;DR

The rationale for reducing long-term reliance on benzodiazepines and benzodiazepine receptor agonists (BZRAs) in favor of agents with more favorable long-term risk profiles is discussed.

Abstract

INTRODUCTION Insomnia is a highly prevalent sleep disorder among Veterans and frequently co-occurs with post-traumatic stress disorder (PTSD), depression, chronic pain, and substance use disorders. AREAS COVERED This review synthesizes the current evidence on pharmacological management of insomnia in Veterans with attention to guideline recommendations, veteran-specific safety considerations, and comorbidity-driven prescribing. We discuss the rationale for reducing long-term reliance on benzodiazepines and benzodiazepine receptor agonists (BZRAs) in favor of agents with more favorable long-term risk profiles. Concurrent prescribing of GABAergic hypnotics with opioids is addressed in the context of existing VA Opioid Safety Initiative policy, FDA labeling, and observational overdose data. Off-label agents such as trazodone and quetiapine continue to be widely used despite limited efficacy evidence for insomnia; their use is best reserved for cases in which better-supported options have failed. EXPERT OPINION Contemporary guidance places cognitive behavioral therapy for insomnia as first-line treatment, while pharmacotherapy is reserved for patients who do not respond to, cannot access, or decline behavioral treatment. The 2025 VA/DoD guideline suggests several medications when pharmacotherapy is used, including daridorexant, doxepin, eszopiclone, lemborexant, suvorexant, zaleplon, and zolpidem, and recommends against antipsychotics, benzodiazepines, and trazodone for chronic insomnia disorder.

View source

Similar papers

Review Open access Oct 2026

Pharmacotherapy for social anxiety disorder: An evidence-based treatment review

Abstract Social anxiety disorder (SAD) is a common and often chronic psychiatric illness characterized by persistent fear of social or performance situations and associated functional impairment and avoidance. Although multiple pharmacologic treatments have been studied, questions remain regarding optimal sequencing of...

J. Strawn, Stephen M. Stahl, Azmi Nasser et al. · 0 citations
Review Open access Oct 2026

Medical cannabis for the treatment of insomnia.

RATIONALE Insomnia is highly prevalent and associated with substantial individual and societal burden, while existing pharmacological treatments are limited by adverse effects and concerns about long-term use. The role of medical cannabis in the treatment of insomnia remains unclear because of limited and heterogeneous...

Lucia B. Varela, Joselyn Elizabeth Miño-Zambrano, Brenda Maura Goncalves Costa et al. · 0 citations
Open access Oct 2026

Long-term outcomes of daridorexant in those with comorbid insomnia.

AIMS AND METHOD Daridorexant is a dual orexin receptor antagonist recently licensed for chronic insomnia disorder. Guidelines recommend it as a second-line treatment for insomnia, after cognitive-behavioural therapy. Initial trials excluded common comorbidities despite comorbid insomnia being the norm, not the exceptio...

Soumya Saladi, Hatem Jouda, T. Yong et al. · 0 citations
Open access Oct 2026

Comprehensive management of chronic insomnia in Spain: a multidisciplinary modified RAND/UCLA consensus with recommendations on daridorexant

Introduction Chronic insomnia is a prevalent 24-hour disorder with significant daytime impact. Its management is frequently complicated by conceptual barriers, limited use of standardised diagnostic tools and prolonged benzodiazepine use, while insomnia is often overlooked or inadequately coded as an independent disord...

Ainhoa Álvarez-Ruiz-Larrinaga, Lorenzo Armenteros, Carmen Bellido et al. · 0 citations
Review Open access Oct 2026

PHARMACOLOGICAL AND PSYCHOTHERAPEUTIC INTERVENTIONS IN THE TREATMENT OF GENERALIZED ANXIETY DISORDER

Generalized Anxiety Disorder (GAD) is a chronic psychiatric condition characterized by excessive worry, autonomic hyperactivity, and significant functional impairment. The objective of this study is to critically review pharmacological and psychotherapeutic interventions in the management of GAD, addressing first-line...

Diego Luiz Leonel Guedes, Luiza Leal de Faria Garcia, Cláudio Hiroto Kitamura et al. · 0 citations
Review Open access 2026

Insomnia as a risk factor in cardiac patients and the treatment approach

The available evidence indicates that insomnia, through autonomic, neuroendocrine, inflammatory, and metabolic dysregulation, contributes to the development of hypertension, atrial fibrillation, and heart failure, with the greatest risk observed in insomnia with objectively short sleep duration.

P. Otašević, J. Vuletić, Dejan Munjiza et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.